Intermediate domain of Receptor-Interacting Protein Kinase 1 (RIPK1) determines the switch between necroptosis and RIPK1 kinase-dependent apoptosis*

Linde Duprez1,2, Mathieu JM Bertrand1,2,#, Tom Vanden Berghe1,2,#, Yves Dondelinger1,2, Nele Festjens1,2, and Peter Vandenabeele1,2

1 Department for Molecular Biomedical Research, VIB, Technologiepark 927, Gent-Zwijnaarde, 9052, Belgium
2 Department of Biomedical Molecular Biology, Ghent University, Technologiepark 927, Gent-Zwijnaarde, 9052, Belgium

#These authors contributed equally

*Running title: RIPK1 kinase-dependent apoptosis

To whom correspondence should be addressed: Peter Vandenabeele, Department for Molecular Biomedical Research, VIB-Ghent University, Technologiepark 927, Gent-Zwijnaarde, 9052, Belgium. Tel: +32 09 33 13760; Fax: +32 09 33 13609. E-mail: Peter.Vandenabeele@dmbr.vib-UGent.be

Keywords: TNF, RIPK1, Smac mimetics, Nec-1, necroptosis, RIPK1 kinase-dependent apoptosis, genetic model

Background: RIPK1 is a central kinase in TNFR1 signaling participating in NF-κB activation, necroptosis and apoptosis.

Results: Ectopic expression of a RIPK1 mutant lacking the Intermediate Domain induces a shift from TNF-induced necroptosis to RIPK1 kinase-dependent apoptosis.

Conclusion: The Intermediate Domain of RIPK1 harbors an anti-apoptotic function.

Significance: Development of a cellular model to identify RIPK1 targets during RIPK1-dependent apoptosis.

SUMMARY

Receptor-Interacting Protein kinase 1 (RIPK1) is an important component of the Tumor Necrosis Factor Receptor 1 (TNFR1) signaling pathway. Depending on the cell type and conditions, RIPK1 mediates MAPK and NF-κB activation as well as cell death. Using a mutant form of RIPK1 (RIPK1ΔID) lacking the Intermediate Domain (ID), we confirm the requirement of this domain for activation of these signaling events. Moreover, expression of RIPK1ΔID resulted in enhanced recruitment of caspase-8 to the TNFR1 complex II component Fas-Associated Death Domain (FADD), which allowed a shift from TNF-induced necroptosis to apoptosis in L929 cells. Addition of the RIPK1 kinase inhibitor necrostatin-1 strongly reduced recruitment of RIPK1 and caspase-8 to FADD and subsequent apoptosis, indicating a role for RIPK1 kinase activity in apoptotic complex formation. Our study shows that RIPK1 has an anti-apoptotic function residing in its ID, and demonstrates a cellular system as an elegant genetic model for RIPK1 kinase-dependent apoptosis that, in contrast to the Smac mimetic model, does not rely on depletion of cellular Inhibitor of Apoptosis Protein 1 and 2 (cIAP1/2).

Tumor necrosis factor (TNF) is a pleiotropic cytokine involved in diverse cellular responses, such as proliferation, differentiation, cell survival, and death. It is a key player in a variety of physiological and pathological processes. TNF signals through two cell surface receptors, TNFR1 and TNFR2, but most of its biological activities are initiated by TNFR1 (1). Ligand binding triggers the sequential formation of different protein complexes (2,3), and the identity of the complex that is formed determines the subsequent intracellular signaling and the cellular response. Upon TNFR1 stimulation, a pro-survival complex I is formed by recruitment of, among others, TNF receptor-associated death domain (TRADD), receptor-interacting protein kinase 1 (RIPK1), TNF
RIPK1 kinase-dependent apoptosis

Although RIPK1 overexpression can induce apoptotic cell death (16-18), many reports conclude that RIPK1 is redundant for death receptor-induced apoptosis (12,19,20). However, in the presence of Smac mimetics, which induce proteasomal degradation of cIAP1/2 and consequently inhibit RIPK1 ubiquitylation in complex I, cells switch to a RIPK1-dependent apoptotic pathway in response to TNF (7,9,19,21-23). In these conditions, kinase active RIPK1 was crucial for the formation of a caspase-8 activating complex, whereas in the absence of Smac mimetics, RIPK1 had no role in apoptosis induction upon TNF stimulation (23). Interestingly, a death complex with similar core-composition has been reported to assemble spontaneously upon cIAP depletion, indicating that cIAPs negatively regulate formation of both RIPK-containing death complexes (24,25). This last complex has been referred to as ripoptosome (24,25).

Besides its function as a central mediator of cell survival and its role in apoptosis induced by Smac mimetics, RIPK1 is important in death receptor-induced necroptosis (19,26). This cell death pathway is initiated by the interplay between RIPK1 and RIPK3 in a complex known as the necosome, in which RIPK1 and RIPK3 interact through a RIP homotypic interaction motif (RHIM) present in both kinases (27-30). Necroptosis is initiated after TNFR1 stimulation in certain cell types or when caspase activation is blocked (19,31-33). Although the RIPK1 kinase activity is dispensable for survival signaling (19,34), the kinase activity of both RIP kinases is crucial for initiating a signaling cascade that leads to necroptotic cell death (27,29,30).

RIPK1 is thus a central molecule in the diverse TNF-induced signaling pathways: it functions as a platform mediating survival signals and as an active kinase during necroptosis and apoptosis in the presence of Smac mimetics. In this study, by exploring the structure-function relationship of RIPK1 in necroptosis, we developed a genetic model for TNF-induced RIPK1-dependent apoptosis in L929sA cells. Our model resembles the model of RIPK1-dependent apoptosis induced by TNF plus Smac mimetics, but has the advantage that no additional factors are required so that this cellular model is very useful to study the downstream targets of RIPK1 kinase leading to apoptosis.

EXPERIMENTAL PROCEDURES

Cell lines – L929sA, a TNF-sensitive derivative of the murine fibrosarcoma cell line L929, was transfected with cDNA encoding the poxviral caspase-8 inhibitor CrmA or the human Fas receptor. The two resultant strains were L929sACrmA and L929sAhFas cells, respectively (32), and the latter is referred to as L929sA for simplicity. The amphotropic packaging cell line Phoenix-Ampho was kindly provided by the Nolan Lab (Kinsella and Nolan, 1996); the cells were transfected with a control vector (pDLZR5-IREs-eGFP, constructed by Dr. C. Stove and compatible with Gateway system, Invitrogen) or with a vector containing the RIPK1ΔID sequence (pDLZR5-ΔID-IREs-eGFP). After 30 hours, the viral supernatant was harvested and used to infect L929sA cells. GFP positive cells were selected by flow cytometry-based cell sorting. All cell lines were cultured in Dulbecco’s modified Eagle’s medium supplemented with 10% fetal calf serum, penicillin (100 IU/ml), streptomycin (0.1 mg/ml), L-glutamine (0.03%), and in the case of Phoenix-Ampho, sodium pyruvate (0.4 mM).

Antibodies, cytokines and reagents – Recombinant human TNF was produced in Escherichia coli and purified to at least 99% homogeneity in our laboratories. The specific biological activity was 3 x 10^7 IU/ml as determined in a standardized cytotoxicity assay on L929sA cells. The caspase peptide inhibitor...
zVAD-fmk (Bachem, Bubendorf, Switzerland) was used at 10 µM. 5-diphenyltetrazolium bromide (MTT) (Sigma Aldrich, St. Louis, MO, USA) was used at 500 µg/ml. Nee-1 (Calbiochem, San Diego, CA, USA) was used at 10 µM. Propidium iodide (Sigma Aldrich, Steinheim, Germany) was used at 3 µM. The following antibodies were used for L929sA cells. Anti-cIAP1 (RIAP1 antibody (35), a kind gift from Dr. RG Korneluk, University of Ottawa, Canada); anti-β-tubulin (HRP) (Abcam, Cambridge, UK); anti-murine caspase-3 (rabbit polyclonal antibody made in-house); anti-cleaved caspase-3 (Asp175). From Cell Signaling Technology, Beverley, MA, USA: anti-phospho-IκBα (Ser32/36) (5A5); anti-p38 MAPK, anti-phospho-p38 MAPK (Thr180/Tyr182); anti-JNK/SAPK. Other antibodies: anti-phospho-IκB/SAPK (pTpY183/185) (Invitrogen, Eugene, OR, USA); anti-caspase-8 (1G-12) (Alexis Biochemicals, San Diego, CA); anti-IκBα (C21) and anti-TRADD (H-278), (Santa Cruz Biotechnology, Santa Cruz, CA, USA); anti-RIPK1 (610459) (BD Biosciences, Franklin Lakes, NJ, USA); anti-RIPK3 (Sigma Aldrich); anti-FADD (12E7, obtained from Dr. Strasser, WEHI, Melbourne, Australia; M19, sc-6036, Santa Cruz Biotechnology).

**Analysis of cell survival and cell death** – Cells were seeded at a density of 7500 cells per well in 96-well BD-imaging plates. After about 20 hours, cells were treated with hTNF (10000 IU/ml) in the presence of Hoechst 33342 (1 µg/ml; Invitrogen, USA) and propidium iodide (PI, 1 µg/ml; Sigma). Images were acquired using a BDPathway™ 855 instrument (BD imaging systems, San José, USA) equipped with an environmental control unit to ensure a constant temperature of 37°C and 5% CO₂ during image acquisition. Images were taken using a 10x objective (Olympus, Center Valley, USA) in a montage of 4x4, including approximately 2000 cells per image and treatment condition. Hoechst 33342-labeling was used to segment the nuclei and to extract Hoechst and PI intensity values of each nucleus, with BD Attovision analysis software (BD imaging systems, San José, USA). The percentage of PI positive nuclei per image was calculated as the percentage of nuclei with PI intensities above the threshold of healthy, untreated nuclei. In other experiments, cell death and DNA fragmentation were analyzed flow cytometrically by measuring PI-emitted fluorescence on an LSR-II with 96-well HTS and FACSDiva software (BD Biosciences) after stimulation with hTNF (10000 IU/ml) and *in situ* PI staining (1 µg/ml). Cell death or loss of plasma membrane integrity was measured on freshly harvested cells. DNA fragmentation or hypoploidy was measured after freezing cells at −70°C and thawing them. To measure cell survival, cells were treated with a concentration gradient of hTNF and survival was determined by an MTT assay following a standard protocol.

**Fluorogenic substrate assay for caspase activity** – The fluorogenic substrate assay was carried out as described (31). Cells were lysed in caspase lysis buffer and cell debris was removed by centrifugation. Caspase activity was measured by incubating 15 µg of protein with 50 µM Ac-DEV-D-MCA (3171-V, Peptide, Scientific Marketing Associate) in 150 µl of cell-free system buffer containing 10 mM Heps, pH 7.4, 220 mM mannitol, 68 mM sucrose, 2 mM NaCl, 2.5 mM KH₂PO₄, 0.5 mM EGTA, 2 mM MgCl₂, 0.5 mM sodium pyruvate, 0.5 mM L-glutamine, and 10 mM dithiothreitol. The release of fluorescent aminomethylcoumarin was measured for 1 h at 2-min intervals by fluorometry (excitation at 360 nm and emission at 480 nm) (Cytofluor; PerSeptiveBiosystems, Cambridge, MA); the maximal rate of increase in fluorescence was calculated (∆F/min).

**RNAi-mediated knockdown** – L929sA cells were transfected in six-well plates according to the manufacturer’s protocol using siRNA targeting caspase-8; TRADD or RIPK3. As a negative control, we used siCONTROL non-targeting siRNA (ON-TARGETplus SMART pool siRNA; Dharmaco, Thermo Fisher Scientific, Waltham, MA, USA). INTERFERin (Polyplus-transfection SA, Illkirch, France) was used as a transfection reagent. After 72 h, L929sA cells were stimulated with hTNF and cell survival or death was determined as described above. Knockdown efficiency was checked by western blot.

**Immunoprecipitation** – For IP of FADD L929sA cells were seeded at 3.5 × 10⁴ cells per 60-cm² petridish. The next day, cells were lysed and scraped in 1 ml NP-40 buffer (150 mM NaCl, 1% NP-40, 10% glycerol, 10 mM Tris pH 8) containing complete, EDTA-free protease inhibitor cocktail tablets (11873580001) and phosphatase inhibitor cocktail tablets (PhosSTOP, 04906837001) (both from Roche Diagnostics Belgium N.V., Vilvoorde, Belgium). Beads were incubated in 5% BSA for
8 h at room temperature before binding of anti-FADD antibody (M19, sc-6036, Santa Cruz Biotechnology) to the beads overnight at 4°C. The next day, FADD was immunoprecipitated at 4°C overnight. Beads were washed three times in NP-40 buffer and boiled in sample buffer before western blot analysis. For immunoprecipitation of processed caspase-8 L929sA cells were lysed in RIPA buffer and incubated for 3 h at 4°C with streptavidin-agarose beads (Invitrogen, S951) that had previously been incubated with biotin-IETD-fmk (MBL, JM-1121-20C).

**High resolution live cell imaging –** L929sA cells were seeded in an 8-well chambered coverglass (NalgeNunc International, Rochester, NY, USA) and stimulated with hTNF (10000 IU/ml) in the presence of Hoechst 33342 (0.5 µg/ml, Invitrogen, USA) and propidium iodide (1 µg/ml, PI, Sigma). Time-lapse microscopy was done using an Application Solution Multi-Dimensional Workstation (AS MDW, Leica Microsystems, Wetzlar, Germany), including a DM IRE2 microscope, HCX PL APO 63x/1.3 glycerin-corrected 37°C objective, 75-W Xenon burner (with monochromator) and a 12-bit CoolSnap HQ Camera. During acquisition, cells were kept at 37°C in a 5% CO2 environment. Cell morphology was observed using differential interference contrast (DIC). Hoechst 33342 and PI were excited at 380 nm and 540 nm, respectively, and emission was detected using a BP340/80/FT400/LP425 filter cube and a BP515-560/FT580/LP590 filter cube, respectively. Z-stack images (1 µm interval) were acquired every 15 min. Maximum intensity projections (for Hoechst 33342 and PI) and autoset images (for DIC) were made for each time point using an in-house script for Fiji public domain imaging software.

**RESULTS**

Ectopic expression of RIPK1ΔID induces a shift from necroptosis to apoptosis in response to TNF – RIPK1 contains a N-terminal Kinase Domain (KD) followed by an Intermediate Domain (ID) and a C-terminal Death Domain (DD) (supplemental Fig. S1A). To study the role of the different RIPK1 domains in TNF-induced necroptosis, we performed a structure-function analysis. We overexpressed the three single-domain mutants (KD, ID and DD) and the three domain-deletion mutants (ΔKD, ΔID and ΔDD) of RIPK1 (supplemental Fig. S1A) in L929sA cells and analyzed the ability of each mutant to induce necrotic cell death. Mouse fibrosarcoma L929sA cells die by necroptosis in response to TNF, even in the absence of caspase inhibitors and transcription or translation inhibitors (31). Nevertheless, all overexpression studies were performed in the presence of the caspase-8 inhibitor CrmA to ensure necrotic conditions. A viability assay showed that ectopic expression of wild-type RIPK1 (WT), RIPK1ΔKD or RIPK1ΔDDD induced cytotoxicity even in absence of any trigger (Fig. 1A and supplemental Fig. S1B). These observations suggest that ectopically expressed RIPK1 can oligomerize in the absence of DD, which was confirmed in HEK293T cells by demonstrating interaction of overexpressed RIPK1ΔADD with full length RIPK1 (Fig. 1B). Our results further indicate that ID is involved in induction of necrotic cell death as ectopic expression of RIPK1ΔID did not induce cell death. Even more, stimulation with TNF resulted in substantially lower induction of necrotic cell death in these cells as compared to L929sA cells expressing the other RIPK1 mutants (Fig. 1A and supplemental Fig. S1C), further demonstrating the involvement of ID in cell death induction.

As RIPK1 is important for activation of NF-κB in several signaling pathways (36), we also analyzed the ability of each RIPK1 mutant to induce an NF-κB-dependent luciferase reporter. Because overexpression of several RIPK1 mutants in L929sA cells rapidly resulted in necrotic death, this assay was performed in HEK293T cells, which are devoid of the necrotic mediator RIPK3 (29). Overexpression of RIPK1ΔID was sufficient to induce activation of NF-κB, whereas overexpression of RIPK1ΔID failed to do so (Fig. 1A and supplemental Fig. S1D), confirming the crucial role of ID in this pathway, which is known to contain several regions responsible for interaction with proteins involved in the NF-κB activation pathway.

We next analyzed whether ectopically expressed RIPK1ΔID acted as dominant negative on TNF-induced NF-κB and MAPK signaling in L929sA cells. In cells expressing RIPK1ΔID and stimulated with TNF, both early and late waves of NF-κB activation were abrogated in comparison to parental cells (Fig. 1C). This abrogation was likely caused by the absence of Lys residue K377 in RIPK1ΔID, which has been reported to act as acceptor site for the polyubiquitin chains that allow recruitment of the TAB-TAK and IKK...
complexes (5,6). Similarly, ectopic expression of RIPK1\(\Delta\ID\) strongly reduced both early and late phosphorylation of p38 and JNK in response to TNF (Fig. 1C). We therefore decided to focus our study on RIPK1\(\Delta\ID\) because this mutant acted as a dominant negative, inhibiting both TNF-induced NF-kB activation and necroptosis in L929sA cells.

Necroptosis depends on the kinases RIPK1 and RIPK3, which interact through their RHIM domain to form the necrosome (28,37). Because the RHIM domain of RIPK1 is situated in its ID, the dominant negative effect of RIPK1\(\Delta\ID\) on TNF-induced necroptosis can be explained by defects in necrosome formation. Intriguingly, in the absence of caspase inhibition, cells expressing RIPK1\(\Delta\ID\) showed more cell death in response to TNF than parental cells (Fig. 2A). Analysis of several biochemical parameters, such as DNA hypoploidy (Fig. 2B), caspase-3 cleavage (Fig. 2C) and caspase activity (Fig. 2D), revealed that cells expressing RIPK1\(\Delta\ID\) underwent apoptosis whereas parental L929sA cells underwent necroptosis. The biochemical assessment of the RIPK1\(\Delta\ID\)-induced shift from necroptosis to apoptosis was confirmed by analysis of cell morphology, which showed typical apoptotic features such as blebbing and DNA condensation (Fig. 2E, bottom panels), whereas parental L929sA cells had a typical necrotic morphology (Fig. 2E, upper panels). Together, these results demonstrate that absence of the ID of RIPK1 causes L929sA cells to respond to TNF by apoptosis rather than by necroptosis. This finding indicates that apoptosis in parental L929sA cells is inhibited by a RIPK1-dependent mechanism that relies on RIPK1 ID.

Ectopic expression of RIPK1\(\Delta\ID\) promotes the formation of a caspase-8-activating complex independently of TRADD – Internalization of TNFR1 induces the transition from a pro-survival complex I to a cytosolic death-inducing complex II that contains FADD, caspase-8, RIPK1 and RIPK3 (2,27). Depending on the stimulus and cell line, other signaling molecules, such as TRADD, might also be present in this complex (2,23).

Our results indicated that distinct functional complexes are formed during necroptotic and RIPK1\(\Delta\ID\)-dependent apoptotic cell death in response to TNF. We therefore analyzed the composition of TNFR1 complex II by immunoprecipitating FADD in parental and RIPK1\(\Delta\ID\)-expressing L929sA cells after different durations of TNF stimulation. We found similar time-dependent increases in recruitment of endogenous RIPK1 to FADD, with a peak between 60 and 120 min in both cell types (Fig. 3A). The recruitment of RIPK1\(\Delta\ID\) to FADD in cells expressing RIPK1\(\Delta\ID\) followed similar kinetics (Fig. 3A). In contrast, recruitment of caspase-8 to FADD two hours after TNF treatment was enhanced only in cells expressing RIPK1\(\Delta\ID\) (Fig. 3A), which is in line with the shift of these cells towards apoptosis. Furthermore, caspase-8 activation in RIPK1\(\Delta\ID\) expressing cells was confirmed by immunoprecipitating processed caspase-8 p45 fragments using biotin-IETD-fmk as an activity based probe (supplemental Fig. S2). Together, those results suggest that absence of RIPK1 ID allows apoptotic signaling by facilitating the formation of the caspase-8 activating complex. In contrast to caspase-8 no substantial levels of TRADD could be detected in the necroptotic or apoptotic cell death-inducing complex (Fig. 3A), illustrating that the presence of TRADD in TNFR1 complex II might vary with cell type and stimulus (2,23).

To confirm the contribution of caspase-8 in TNF-induced apoptosis in cells expressing RIPK1\(\Delta\ID\), and to further investigate the role of TRADD therein, cells deficient in caspase-8 or TRADD were generated by an RNAi technique (Fig. 3D, G). Knockdown of caspase-8 abrogated TNF-induced caspase activity (Fig. 3B). However, this did not rescue the cells from TNF-induced cell death (Fig. 3C). On the contrary, cell death was accelerated, even when caspase activity was absent, indicating that cells underwent a shift back to caspase-independent necroptosis. In these conditions, Nec-1 or knockdown of RIPK3 strongly diminished TNF-induced cell death (supplemental Fig. S3A-B). Addition of the pan-caspase inhibitor zVAD-fmk to L929sA cells expressing RIPK1\(\Delta\ID\) induced a similar shift to necroptosis in response to TNF (supplemental Fig. S3C). These results illustrate that caspase-8 deficiency or inhibition favors necroptosis, as demonstrated by others in cell lines (19,31,38) and recently also in vivo (39-41). On the other hand, knockdown of TRADD affected neither caspase activity nor apoptotic cell death (Fig. 3 E-G), which is in agreement with the observation that TRADD is not present in TNFR1 complex II when RIPK1\(\Delta\ID\) is expressed. This resembles the
apoptotic pathway activated when TNF and Smac mimetics are used together (23).

In the absence of the ID of RIPK1, TNF-induced formation of the caspase-8 activating complex II requires RIPK1 kinase activity – RIPK1 kinase activity is crucial not only for TNF-induced necroptosis, but also for apoptosis under specific conditions, e.g., after TNF stimulation in the presence of Smac mimetics (23,42,43). Therefore, we investigated whether RIPK1 kinase activity contributes to TNF-induced apoptosis in cells expressing RIPK1∆ID. Inhibition of RIPK1 kinase activity by Nec-1 almost completely inhibited the apoptotic response to TNF (Fig. 4A), and this inhibition persisted for 18 hours after stimulation (Fig. 4B). These results clearly indicate that activation of RIPK1 kinase activity is causally linked to TNF-induced apoptosis in this cellular system.

Next, we investigated whether Nec-1 affects the formation of TNFR1 complex II. In line with the observation that Nec-1 rescued cells expressing RIPK1∆ID from TNF-induced apoptosis, Nec-1 pretreatment almost completely abrogated the interaction of caspase-8 with FADD (Fig. 4C). In addition, recruitment of endogenous RIPK1 and ectopic RIPK1∆ID in the FADD complex was significantly decreased. Collectively, these results indicate that RIPK1∆ID promotes the formation of a caspase-8-activating complex by a mechanism that requires RIPK1 kinase activity.

Remarkably, our cellular model of RIPK1 kinase-dependent apoptosis is very similar to the TNF plus Smac mimetic model. Smac mimetics induce autodegradation of cIAPs, preventing TAK1 recruitment and activation of the MAPK and NF-κB pathways and preventing RIPK1 from integrating into and activating death complexes (7,11-13). Depending on the cell line, this enhances either necrotic or apoptotic cell death. Because of the close resemblance of our model to the Smac mimetic model, we checked whether ectopic expression of RIPK1∆ID affected cIAP1 levels after TNF stimulation. cIAP1 levels remained unchanged during RIPK1-dependent apoptosis in cells expressing RIPK1∆ID (Fig. 4D).

In conclusion, our cellular system provides an elegant genetic model for studying RIPK1 kinase-dependent apoptosis. In contrast to the TNF plus Smac mimetic model, in our model RIPK1 kinase-dependent apoptosis does not rely on cIAP depletion making it particularly interesting to identify RIPK1 targets in apoptotic signaling.

Reconstitution of RIPK1-deficient cells with RIPK1∆ID leads to RIPK1-kinase dependent apoptosis – To evaluate the contribution of endogenous RIPK1 to our observations, L929sA cells deficient in RIPK1 were generated by stable expression of a miRNA directed against the 3’ UTR of the RIPK1 mRNA (Fig. 5A). As previously reported, L929sA cells deficient in RIPK1 switch from a necrotic to an apoptotic pathway in response to TNF, which occurs independently of RIPK1 kinase activity [(44) and Fig. 5B, D]. Interestingly, expression of RIPK1∆ID in RIPK1-depleted cells delayed caspase activation and shifted the cell death response to RIPK1 kinase-dependent apoptosis as Nec-1 prevented against caspase activation and consequent cell death (Fig. 5C, D). These results further suggest that RIPK1 ID prevents RIPK1 kinase activity from initiating apoptotic signaling. Interestingly, whereas addition of zVAD-fmk to wild-type L929sA cells expressing RIPK1∆ID shifted the response to necrosis (supplemental Fig. S3C), zVAD-fmk protected the RIPK1-depleted cells reconstituted with RIPK1∆ID (Fig. 5E). These results indicate that endogenous RIPK1 is required for the switch back to the necrotic signaling cascade in the wild-type L929sA cells expressing RIPK1∆ID.

DISCUSSION

The last decade of research revealed an important role for RIPK1 in TNFR1 signaling pathways, involving different RIPK1 domains and posttranslational modifications (28,45). Most cell lines respond to TNF by activating pro-survival or pro-inflammatory pathways and require the addition of transcriptional or translational inhibitors for cell death to occur. Alternatively, addition of Smac mimetics has been shown to greatly sensitize cells to death, which in most cell lines is executed via an apoptotic program. Although RIPK1 is dispensable for the classical apoptotic pathway induced by TNF, in the presence of Smac mimetics RIPK1 is converted into a pro-death molecule that is required for the formation of a caspase-8 activating complex (7,9,19,21-23). In this study, by performing a structure-function analysis of RIPK1 in TNF signaling, we observed that ectopic expression of a RIPK1
mutant lacking the intermediate domain (RIPK1ΔID) in L929sA cells converted the cellular response to TNF from RIPK1 kinase-dependent necroptosis to RIPK1 kinase-dependent apoptosis. Thus, our experimental setup represents a genetic cellular model for RIPK1 kinase-dependent apoptosis, which resembles the apoptotic pathway in response to TNF plus Smac mimetics in several aspects (23). First, because in both cellular systems RIPK1 cannot be conjugated with non-degradative polyubiquitin chains, TNFR1 complex I signaling is abrogated. Second, formation of the caspase-8-activating complex is enhanced in both systems, and the complex is devoid of TRADD. This indicates that RIPK1 kinase-dependent apoptosis is different from classical apoptosis, in which TRADD serves as an initial platform for recruitment of FADD and caspase-8 (2,44,46,47). Third, both pathways require kinase-active RIPK1 for formation of the caspase-8-activating complex and subsequent cell death, which were abrogated in the presence of kinase-inactive RIPK1.

The observed shift from TNF-induced necrosis to apoptosis upon deletion of the ID domain suggests that the ID domain harbors an anti-apoptotic function. Indeed, RIPK1ΔID lacks both the K377 ubiquitylation site and the RHIM domain, the absence of which eliminates both survival signaling and necroptotic signaling, respectively. Therefore, it is conceivable that the simultaneous deletion of both functions is the cause of the observed shift in cell death mode from necroptosis to apoptosis. However, blockade of survival signaling and necroptosis in parental L929sA cells by depletion of both cIAPs and RIPK3, does not cause a shift to apoptosis but instead cells survive (11), indicating that an additional anti-apoptotic function resides in RIPK1 ID.

Depleting caspase-8 in RIPK1ΔID expressing cells shifted the TNF response back to RIPK-dependent necroptosis. Thus, our data illustrate that TNF-induced cell death in L929sA cells is regulated at several levels by RIPK1 ID and caspase-8. Parental cells by default activate RIPK1/RIPK3 kinase-dependent necroptosis. However, deleting the RIPK1 ID apparently removes an anti-apoptotic signal emanating from the ID, and the result is RIPK1 kinase-dependent apoptosis. In turn, depletion of caspase-8 in these conditions redirects the cell death response to RIPK1/RIPK3 kinase-dependent necroptosis. These results are in line with the observation that the pro-apoptotic proteins caspase-8 and FADD negatively regulate RIPK1/RIPK3-dependent necroptosis not only on the cellular level (19,31,38), but also in vivo (39-41). Deletion of RIPK1 and RIPK3 rescued embryonic lethality of FADD and caspase-8 deficiency in mice, respectively, indicating that embryonic lethality in these mice is caused by massive necrosis (39-41). As blockade of caspase activation in RIPK1-depleted L929sA cells reconstituted with RIPK1ΔID did not result in a shift to necrosis, we think that the necrotic signaling in L929sA cells expressing both endogenous RIPK1 and RIPK1ΔID is due to recruitment of RIPK3 via RHIM-mediated interaction by endogenous RIPK1.

Our genetic cellular model may have some advantages over the Smac mimetic model for studying RIPK1 kinase-dependent apoptotic pathways. Smac mimetics induce autodegradation of cIAP1 and cIAP2 and affect XIAP activity, thereby abrogating all their functions, which extend beyond mere inhibition of RIPK1 polyubiquitylation. For example, XIAP effectively binds and inhibits caspase-3, -7 and -9, whereas cIAP1/2 might target caspase-3 and -7 for proteasome-mediated degradation (48,49). Hence, Smac mimetics not only sensitize for cell death by their action on RIPK1 but also by relieving caspase inhibition. Since expression of RIPK1ΔID specifically targets RIPK1 signaling in TNFR1 complex I without affecting the function of XIAP and other functions of cIAP1/2 as is the case when using Smac mimetics, the L929sA cell line expressing RIPK1ΔID can be considered an elegant genetic model of TNF-induced apoptosis that is RIPK1 kinase-dependent. This cellular model of RIPK1 kinase-dependent apoptosis has several potential applications. It is of particular interest for investigating the underlying mechanisms that drive cells to either RIPK1/RIPK3 kinase-dependent necroptosis in parental L929sA cells or to apoptosis in RIPK1ΔID expressing L929sA cells in response to the same death stimulus. To date, downstream substrates of RIPK1 during necroptotic or apoptotic signaling are unknown. Use of this cellular system in phosphoproteomic studies will allow identification of the differential RIPK1-mediated phosphoproteome in both signaling pathways.

Finally, our results shed new light on the use of necrostatin-1 in vivo. Nec-1 is currently used as an inhibitor of necroptosis and has been proven successful in the treatment of several
RIPK1 kinase-dependent apoptosis

pathological conditions such as neurodegenerative diseases, ischemia-reperfusion injury, myocardial infarction and head trauma (50-53). However, one should interpret these results with caution since RIPK1 kinase activity is not exclusively linked to TNF-induced necroptosis, but in some conditions is also critical for activating caspase-8 in TNFR1 complex II. RIPK1 kinase-dependent apoptosis has been demonstrated in the presence of Smac mimetics (23) as well as after stimulation with TWEAK, which induces cIAP degradation upon binding to its cognate receptor FN14 and thus represents a more physiological context in which RIPK1 kinase-dependent apoptosis may occur (54,55). Hence, protection by Nec-1 points to involvement of the RIPK1 kinase activity, which does not necessarily mean that necroptosis is implicated. In these studies, precise analysis of cell death mode and/or validation of the results in RIPK3-deficient conditions is therefore appropriate.

REFERENCES

1. Wilson, N. S., Dixit, V., and Ashkenazi, A. (2009) Nat Immunol 10, 348-355
2. Micheau, O., and Tschopp, J. (2003) Cell 114, 181-190
3. Schneider-Brachert, W., Tchikov, V., Neumeyer, J., Jakob, M., Winoto-Morbach, S., Held-Feindt, J., Heinrich, M., Merkel, O., Ehrenschwender, M., Adam, D., Mentlein, R., Kabelitz, D., and Schutze, S. (2004) Immunity 21, 415-428
4. Wajant, H., and Scheurich, P. (2011) Febs J 278, 862-876
5. Ea, C. K., Deng, L., Xia, Z. P., Pineda, G., and Chen, Z. J. (2006) Molecular cell 22, 245-257
6. Li, H., Kobayashi, M., Blonska, M., You, Y., and Lin, X. (2006) The Journal of biological chemistry 281, 13636-13643
7. Bertrand, M. J., Milutinovic, S., Dickson, K. M., Ho, W. C., Boudreau, A., Durkin, J., Gillard, J. W., Jaquith, J. B., Morris, S. J., and Barker, P. A. (2008) Molecular cell 30, 689-700
8. Mahoney, D. J., Cheung, H. H., Mrad, R. L., Plenchette, S., Simard, C., Enwere, E., Arora, V., Mak, T. W., Lacasse, E. C., Waring, J., and Korneluk, R. G. (2008) Proc Natl Acad Sci U S A 105, 11778-11783
9. Varfolomeev, E., Goncharov, T., Fedorova, A. V., Dynek, J. N., Zobel, K., Deshayes, K., Fairbrother, W. J., and Vucic, D. (2008) J Biol Chem 283, 24292-24299
10. O'Donnell, M. A., Legarda-Addison, D., Skountzos, P., Yeh, W. C., and Ting, A. T. (2007) Curr Biol 17, 418-424
11. Legarda-Addison, D., Hase, H., O'Donnell, M. A., and Ting, A. T. (2009) Cell Death Differ 16, 1279-1288
12. Wong, W. W., Gentle, I. E., Nachbur, U., Anderton, H., Vaux, D. L., and Silke, J. (2009) Cell death and differentiation 18, 656-665
13. Grimm, S., Stanger, B. Z., and Leder, P. (1996) Proc Natl Acad Sci U S A 93, 10923-10927
14. Stanger, B. Z., Leder, P., Lee, T. H., Kim, E., and Seed, B. (1995) Cell 81, 513-523
22. Vince, J. E., Wong, W. W., Khan, N., Feltham, R., Chau, D., Ahmed, A. U., Benetatos, C. A., Chunduru, S. K., Condon, S. M., McKinlay, M., Brink, R., Leverkus, M., Tergaonkar, V., Schneider, P., Callus, B. A., Koentgen, F., Vaux, D. L., and Silke, J. (2007) Cell 131, 682-693
23. Wang, L., Du, F., and Wang, X. (2008) Cell 133, 693-703
24. Feoktistova, M., Gesericke, P., Kellert, B., Dimitrova, D. P., Langlais, C., Hupe, M., Cain, K., MacFarlane, M., Hacker, G., and Leverkus, M. (2011) Mol Cell 43, 449-463
25. Tenev, T., Bianchi, K., Darding, M., Broemer, M., Langlais, C., Wallberg, F., Zachariou, A., Lopez, J., MacFarlane, M., Cain, K., and Meier, P. (2011) Mol Cell 43, 432-448
26. Vanden Berghe, T., Vanlangenakker, N., Parthoens, E., Deckers, W., Devos, M., Festjens, N., Guerin, C. J., Brunk, U. T., Declercq, W., and Vandenabeele, P. (2010) Cell Death Differ 17, 922-930
27. Cho, Y. S., Challa, S., Moquin, D., Genga, R., Ray, T. D., Guildford, M., and Chan, F. K. (2009) Cell 137, 1112-1123
28. Declercq, W., Vanden Berghe, T., and Vandenabeele, P. (2009) Cell 138, 229-232
29. He, S., Wang, L., Miao, L., Wang, T., Du, F., Zhao, L., and Wang, X. (2009) Cell 137, 1100-1111
30. Zhang, D. W., Shao, J., Lin, J., Zhang, N., Lu, B. J., Lin, S. C., Dong, M. Q., and Han, J. (2009) Science 325, 332-336
31. Vercammen, D., Beyaert, R., Denecker, G., Goossens, V., Van Loo, G., Declercq, W., Grooten, J., Fiers, W., and Vandenabeele, P. (1998) J Exp Med 187, 1477-1485
32. Vercammen, D., Brouckaert, G., Denecker, G., Van de Craen, M., Declercq, W., Fiers, W., and Vandenabeele, P. (1998) J Exp Med 188, 919-930
33. Lin, Y., Choksi, S., Shen, H. M., Yang, Q. F., Hur, G. M., Kim, Y. S., Tran, J. H., Nedospasov, S. A., and Liu, Z. G. (2004) Journal of Biological Chemistry 279, 10822-10828
34. Lee, T. H., Shank, J., Cusson, N., and Kelliher, M. A. (2004) The Journal of biological chemistry 279, 33185-33191
35. Holcik, M., Lefebvre, C. A., Hicks, K., and Korneluk, R. G. (2002) BMC Genomics 3, 5
36. Festjens, N., Vanden Berghe, T., Cornelis, S., and Vandenabeele, P. (2007) Cell Death and Differentiation 14, 400-410
37. Vandenabeele, P., Galluzzi, L., Vanden Berghe, T., and Kroemer, G. (2010) Nat Rev Mol Cell Biol 11, 700-714
38. Bell, B. D., Leverrier, S., Weist, B. M., Newton, R. H., Arechiga, A. F., Luhrs, K. A., Morrissette, N. S., and Walsh, C. M. (2008) Proceedings of the National Academy of Sciences of the United States of America 105, 16677-16682
39. Kaiser, W. J., Upton, J. W., Long, A. B., Livingston-Rosanoff, D., Daley-Bauer, L. P., Hakem, R., Caspary, T., and Mocarski, E. S. (2011) Nature 471, 368-372
40. Oberst, A., Dillon, C. P., Weinlich, R., McCormick, L. L., Fitzgerald, P., Pop, C., Hakem, R., Salvesen, G. S., and Green, D. R. (2011) Nature 471, 363-367
41. Zhang, H., Zhou, X., McQuade, T., Li, J., Chan, F. K., and Zhang, J. (2011) Nature 471, 373-376
42. Degterev, A., Hitomi, J., Germscheid, M., Ch’en, I. L., Korkina, O., Teng, X., Abbott, D., Cuny, G. D., Yuan, C., Wagner, G., Hedrick, S. M., Gerber, S. A., Lugovskoy, A., and Yuan, J. (2008) Nature chemical biology 4, 313-321
43. Knox, P. G., Davies, C. C., Ioannou, M., and Eliopoulos, A. G. (2011) J Cell Biol 192, 391-399
44. Vanlangenakker, N., Bertrand, M. J., Bogaert, P., Vandenabeele, P., and Vanden Berghe, T. (2011) Cell Death Dis 2, e230
45. O’Donnell, M. A., and Ting, A. T. (2011) Febs J 278, 877-887
46. Ermolaeva, M. A., Michallet, M. C., Papadopoulou, N., Utermohlen, O., Kranidiotis, K., Kollias, G., Tschopp, J., and Pasparakis, M. (2008) Nat Immunol 9, 1037-1046
47. Pobezinskaya, Y. L., Kim, Y. S., Choksi, S., Morgan, M. J., Li, T., Liu, C., and Liu, Z. (2008) Nat Immunol 9, 1047-1054
48. Gyrd-Hansen, M., and Meier, P. (2010) Nat Rev Cancer 10, 561-574
49. Choi, Y. E., Butterworth, M., Malladi, S., Duckett, C. S., Cohen, G. M., and Bratton, S. B. (2009) J. Biol. Chem., M807550200
RIPK1 kinase-dependent apoptosis

50. Degterev, A., Huang, Z., Boyce, M., Li, Y., Jagtap, P., Mizushima, N., Cuny, G. D., Mitchison, T. J., Moskowitz, M. A., and Yuan, J. (2005) Nature chemical biology 1, 112-119

51. Lim, S. Y., Davidson, S. M., Mocanu, M. M., Yellon, D. M., and Smith, C. C. (2007) Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 21, 467-469

52. You, Z., Savitz, S. I., Yang, J., Degterev, A., Yuan, J., Cuny, G. D., Moskowitz, M. A., and Whalen, M. J. (2008) J Cereb Blood Flow Metab 28, 1564-1573

53. Yuan, J., Lipinski, M., and Degterev, A. (2003) Neuron 40, 401-413

54. Ikner, A., and Ashkenazi, A. (2011) J Biol Chem 286, 21546-21554

55. Vince, J. E., Chau, D., Callus, B., Wong, W. W., Hawkins, C. J., Schneider, P., McKinlay, M., Benetatos, C. A., Condon, S. M., Chunduru, S. K., Yeoh, G., Brink, R., Vaux, D. L., and Silke, J. (2008) J Cell Biol 182, 171-184

Acknowledgments – We thank Sigrid Cornelis, Saskia Lippens and Franky Van Herreweghe for scientific discussion, Isabel Vanoverberghe, Wilma Burnm, and Ann Meeuws for expert technical assistance, and Amin Bredan for excellent editing. MB, TVB and NF are holders of a postdoc mandate from the FWO. YD holds a PhD grant from the IWT. MB has a tenure track position in the Multidisciplinary Research Program of Ghent University (GROUP-ID). Research in the Vandenabeele group is supported by European grants (FP6 AppTrain, MRTN-CT-035624; FP7 EC RTD Integrated Project, Apo-Sys, FP7-200767; Euregional PACT II), Belgian grants (Interuniversity Attraction Poles, IAP 6/18), Flemish grants (Research Foundation Flanders, FWO G0875.11 and FWO G0973.11), Ghent University grants (MRP, GROUP-ID consortium) and grants from Flanders Institute for Biotechnology (VIB). PV holds a Methusalem grant (BOF09/01M00709) from the Flemish Government.

FIGURE LEGENDS

FIGURE 1. Absence of the RIPK1 intermediate domain inhibits TNF-induced necroptosis and pro-survival signaling. A. Overview of the results of the structure-function analysis of RIPK1 in TNF signaling. A series of RIPK1 mutants was overexpressed in HEK293T or L929sACrmA cells as indicated and their effect on activation of NF-κB, induction of necroptosis, and TNF-induced necroptosis was analyzed. KD, Kinase Domain; ID, Intermediate Domain; DD, Death Domain; -, no induction of NF-κB or necroptosis; +, induction of NF-κB or necroptosis; ND, not done due to toxic effect of overexpression. B. V5-tagged mRIPK1ΔDD and mRIPK1 were overexpressed together with flag-tagged hRIPK1 in HEK293T cells and their interaction was analyzed by flag-mediated immunoprecipitation. C. Parental and RIPK1ΔID-expressing L929sA cells were stimulated with hTNF (10000 IU/ml) for the indicated durations. Lysates were made and analyzed for phospho-IκB and total IkB (upper panel), phospho-JNK and total JNK (middle panel), and phospho-p38 and total p38 (lower panel). * indicates a nonspecific band.

FIGURE 2. Ectopic expression of RIPK1ΔID induces a shift from necroptosis to apoptosis in response to TNF. A. Parental and RIPK1ΔID-expressing L929sA cells were stimulated with hTNF (10000 IU/ml) and cell death (% PI positive cells) was analyzed by flow cytometry. B. Cells from A were freeze-thawed and their content of hypoploid DNA was analyzed by flow cytometry. C, D. Parental and RIPK1ΔID-expressing L929sA cells were stimulated with hTNF (10000 IU/ml) for indicated time points. Lysates were collected and analyzed for caspase-3 cleavage (C) and caspase activity (D). Error bars represent standard deviation of biological triplicates. E. Parental and RIPK1ΔID-expressing L929sA cells were stained with Hoechst 33242 (blue) and PI (red) for live-cell imaging and monitored for 12 hours after stimulation with hTNF (10000 IU/ml). Representative overlay snapshots of the fluorescent and transmitted light images at the indicated time points after hTNF stimulation are shown. Scale bar, 20 µm.
**FIGURE 3. Ectopic expression of RIPK1ΔID promotes the formation of a caspase-8 activating complex.** A. Parental and RIPK1ΔID-expressing L929sA cells were stimulated with hTNF (10000 IU/ml) after pretreatment with zVAD-fmk (20 µM). Lysates were made at the indicated time points and FADD was immunoprecipitated. Levels of FADD, caspase-8, RIPK1, RIPK1ΔID and TRADD in the immunocomplex were measured by western blot. * indicates nonspecific bands. B, C. L929sA cells expressing RIPK1ΔID were transfected with siRNA targeting caspase-8 before stimulation with hTNF (10000 IU/ml). Caspase activity (B) and cell death (C) (% PI-positive cells measured using a BDPathway™ 855 instrument) were analyzed at the indicated time points. D. Western blot showing efficiency of caspase-8 knockdown. E, F. L929sA cells expressing RIPK1ΔID were transfected with siRNA targeting TRADD before stimulation with hTNF (10000 IU/ml). Caspase activity (E) and cell death (F) (% PI-positive cells measured using a BDPathway™ 855 instrument) were analyzed at the indicated time points. G. Western blot showing efficiency of TRADD knockdown. Error bars represent standard deviation of biological triplicates.

**FIGURE 4. TNF-induced formation of the caspase-8 activating complex II and consequent apoptosis are dependent on RIPK1 kinase activity.** A, B. L929sA cells expressing RIPK1ΔID were pretreated with Nec-1 (10 µM) for 1 h and stimulated with hTNF (10000 IU/ml). Cell death (% PI-positive cells) was analyzed by flow cytometry (A) or cell survival was measured 20 h after hTNF treatment by MTT (B). Error bars represent standard deviation of biological triplicates. C. Parental and RIPK1ΔID-expressing L929sA cells were stimulated with hTNF (10000 IU/ml) after treatment with zVAD-fmk (20 µM) and Nec-1 (10 µM). Lysates were made at indicated time points and FADD was immunoprecipitated. Levels of FADD, caspase-8, RIPK1, RIPK1ΔID and TRADD in the immunocomplex were measured by western blot. * indicates nonspecific bands. D. Parental and RIPK1ΔID-expressing L929sA cells were stimulated with hTNF (10000 IU/ml) for the indicated durations. Lysates were made and analyzed for cIAP1 levels by western blot.

**FIGURE 5. Ectopic expression of RIPK1ΔID in RIPK1-depleted cells shifts the cell death response to apoptosis inhibited by Nec-1.** L929sA cells were transduced with a miRNA directed against the 3’ UTR of the RIPK1 mRNA (RIPK1i) and reconstituted with an empty vector (EV) or RIPK1ΔID. A. Expression levels of endogenous RIPK1 and RIPK1ΔID in parental L929sA cells and L929sA-RIPK1i + EV or RIPK1ΔID were analyzed by western blot. B. C. RIPK1-depleted L929sA cells reconstituted with EV (B) or RIPK1ΔID (C) were stimulated with hTNF (10000 IU/ml) after treatment with Nec1 (10 µM) and cell death levels were analyzed via PI-uptake. D. Lysates were made from cells in B and C and caspase activity was analyzed via DEVDase activity. E, RIPK1-depleted L929sA cells reconstituted with RIPK1ΔID were stimulated with hTNF (10000 IU/ml) after treatment with zVAD-fmk (20 µM) and cell death levels were analyzed via PI-uptake. Error bars represent standard deviation of biological duplicates.
Figure 1

A

|            | EV | WT | KD | ID | DD | ΔKD | ΔID | ΔDD |
|------------|----|----|----|----|----|-----|-----|-----|
| Activation of NF-κB HEK293T | -  | +  | -  | +  | -  | +   | -   | +   |
| Induction of necroptosis L929sACrmA | -  | +  | -  | -  | -  | +   | -   | +   |
| TNF-induced necroptosis L929sACrmA | +  | ND | +  | +  | +  | ND  | -   | ND  |

B

|          | V5 | FLAG | LYS388S | IP FLAG |
|----------|----|------|---------|---------|
| mRIPK1-V5 | +  | +    | +       | +       |
| mRIPK1-ΔDD-V5 | +  | +    | +       | +       |
| FLAG-hRIPK1 | +  | +    | +       | +       |

C

| Parental | RIPK1;ΔID |
|----------|-----------|
| hTNF (min) 0 5 10 15 30 60 120 240 | 0 5 10 15 30 60 120 240 |
| P-IκB | +         | *          |
| IκB | +         | +          |
| Tubulin | +        | +          |
| P-JNK | +         | +          |
| JNK | +         | +          |
| Tubulin | +        | +          |
| P-p38 | +         | +          |
| p38B | +         | +          |
| Tubulin | +        | +          |
RIPK1 kinase-dependent apoptosis

**Figure 2**

A. % PI positive cells

B. % cells with hypoploid DNA

C. Casp-3

D. DEVDase activity

E. Immunofluorescence images

---

Downloaded from http://www.jbc.org/
Figure 3

A

IP FADD

|         | Parental | RIPK1ΔID |
|---------|----------|----------|
| hTNF (min) | Ctrl 0 30 60 120 180 | Ctrl 0 30 60 120 180 |
| FADD    |          |          |
| Caspase-8 |        |          |
| RIPK1    |        |          |
| TRADD   |          |          |

Whole cell lysates

|         | Parental | RIPK1ΔID |
|---------|----------|----------|
| hTNF (min) | 0 30 60 120 180 | 0 30 60 120 180 |
|          |          |          |

B

[Graph showing enzymatic activity over hours after hTNF treatment]

C

[Graph showing percent positive cells over hours after hTNF treatment]

D

[Graph showing Caspase-8 expression over hours after hTNF treatment]

E

[Graph showing enzymatic activity over hours after hTNF treatment]

F

[Graph showing percent positive cells over hours after hTNF treatment]

G

[Graph showing TRADD expression over hours after hTNF treatment]
Figure 4

A

B

C

IP FADD

RIPK1ΔID

RIPK1ΔID + Nec-1

hTNF (min) Ctrl 0 30 60 120 180 Ctrl 0 30 60 120 180

FADD

Caspase-8

RIPK1

TRADD

D

Whole cell lysates

RIPK1ΔID

RIPK1ΔID + Nec-1

hTNF (min) 0 30 60 120 180 0 30 60 120 180

cIAP1

Tubulin

RIPK1 kinase-dependent apoptosis
**Figure 5**

A

![Western blot analysis of RIPK1 and RIPK1ΔID](image)

**RIPK1 kinase-dependent apoptosis**

B

![Bar graph showing % PI positive cells](image)

C

![L929sA-RIPK1i + RIPK1ΔID](image)

D

![Bar graph showing DEVDase activity](image)

E

![L929sA-RIPK1i + RIPK1ΔID](image)
Intermediate domain of receptor-interacting protein kinase 1 (RIPK1) determines the switch between necroptosis and RIPK1 kinase-dependent apoptosis
Linde Duprez, Mathieu J. M. Bertrand, Tom Vanden Berghe, Yves Dondelinger, Nele Festjens and Peter Vandenabeele

J. Biol. Chem. published online February 23, 2012

Access the most updated version of this article at doi: 10.1074/jbc.M111.288670

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

Supplemental material:
http://www.jbc.org/content/suppl/2012/02/23/M111.288670.DC1